Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activating mutations in TOR are in similar structures as oncogenic mutations in PI3KCalpha.

ACS chemical biology - 18 Dec 2009

Sturgill Thomas W, Hall Michael N

Abstract excerpt

TOR (Target of Rapamycin) is a highly conserved Ser/Thr kinase and a central controller of cell growth. Using the crystal structure of the related lipid kinase PI3KCgamma, we built a model of the catalytic region of TOR, from the FAT domain to near the end of the FATC domain. The model reveals th...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Triphosphate
Share to Catalytic Domain
Share to Crystallography, X-Ray

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Intracellular Signaling Peptides and Proteins

Share to Phosphatidylinositol 3-Kinases

Share to Schizosaccharomyces

Share to Schizosaccharomyces pombe Proteins

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 19902965
DOI: 10.1021/cb900193e
PMCID: PMC2796128

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19902965-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activating mutations in TOR are in similar structures as oncogenic mutations in PI3KCalpha.PMID 19902965Read ↗

Activating mutations of TOR (target of rapamycin).Semantic proximity Read ↗

Somatic mutations in PI3Kα: Structural basis for enzyme activation and drug designSemantic proximity Read ↗

Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.Semantic proximity Read ↗

Drugging the PI3 Kinome: From Chemical Tools to Drugs in the ClinicSemantic proximity Read ↗

Protein kinase activity and identification of a toxic effector domain of the target of rapamycin TOR proteins in yeast.Semantic proximity Read ↗

Phosphorylation and Driver Mutations in PI3Kα and PTEN Autoinhibition.Semantic proximity Read ↗

PI3K Driver Mutations: A Biophysical Membrane-Centric Perspective.Semantic proximity Read ↗

Structural Insights into TOR SignalingSemantic proximity Read ↗

Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit.Semantic proximity Read ↗

Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.Semantic proximity Read ↗

Molecular Basis of the Rapamycin Insensitivity of Target Of Rapamycin Complex 2.Semantic proximity Read ↗

Identification of TOR signaling complexes: more TORC for the cell growth engine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.